Loading...
Loading...
MDXG| Name | Value |
|---|---|
| Revenues | 87.2M |
| Cost of Revenue | 15.0M |
| Gross Profit | 72.2M |
| Operating Expense | 48.7M |
| Operating I/L | 23.4M |
| Other Income/Expense | -0.2M |
| Interest Income | 0.0M |
| Pretax | 23.2M |
| Income Tax Expense | 5.6M |
| Net Income/Loss | 17.6M |
MiMedx Group, Inc. specializes in developing and distributing placental tissue allografts for wound care, burn, surgical, and non-operative sports medicine sectors. Their patented PURION process retains the tissue's biological properties and regulatory proteins, producing products like EpiFix, AmnioFix, EpiCord, AmnioCord, and AMNIOBURN. These allografts are used for chronic wound treatment, surgical recovery, and burn care. The company generates revenue by selling its products through a direct sales force, independent sales agents, and distributors in the United States. Additionally, it offers allografts for dental applications on an original equipment manufacturer basis.
